Physician-supervised multi-axis endocrine support — thyroid, adrenal, pituitary, and gonadal hormones evaluated and optimized as an interconnected system, not in isolation.
Endocrine Support
Physician-supervised multi-axis endocrine support — thyroid, adrenal, pituitary, and gonadal hormones evaluated and optimized as an interconnected system, not in isolation.
This content is for educational purposes only. It does not constitute medical advice or replace clinical consultation. Hormone optimization requires physician evaluation, laboratory confirmation, and individualized management per established clinical guidelines.
Endocrine Support: Comprehensive Multi-Axis Programs
The endocrine system is not a collection of independent glands producing independent hormones — it is a tightly integrated regulatory network in which every axis communicates with and influences every other. The HPA, HPT, HPG, insulin/IGF-1, and growth hormone axes all operate as a coordinated whole. This integration is clinically important because addressing one axis in isolation often produces incomplete results.
Endocrine Support at Advanced Vitality Group is the program that addresses this integrated perspective. A patient with persistent fatigue treated for hypothyroidism but remaining symptomatic may have concurrent adrenal dysfunction, low DHEA-S, or insulin resistance. An executive with low testosterone who starts TRT but sees only partial symptom improvement may have chronic HPA axis dysregulation. Endocrine Support programs systematically evaluate all five axes and coordinate interventions.
Key Takeaways
The HPA, HPT, HPG, and insulin/IGF-1 axes are deeply interconnected — dysfunction in one axis commonly impairs the others. Treating single axes in isolation is a common cause of partial treatment response.
Chronic cortisol elevation simultaneously suppresses testosterone, impairs T4→T3 thyroid conversion, reduces growth hormone pulsatility, and worsens insulin resistance.
The Free T3:reverse T3 ratio provides more clinical information about cellular thyroid activity than TSH alone — patients with normal TSH but suboptimal T3 conversion frequently have symptoms of hypothyroidism.
DHEA-S is both an adrenal biomarker and a direct modulator of cortisol biology — it counterbalances cortisol's catabolic and immunosuppressive effects and declines 80–90% between ages 25 and 75.
IGF-1 — the primary mediator of growth hormone action — supports tissue repair, lean mass, skin quality, and bone density. Optimizable through sleep, exercise, adequate caloric intake, and where GH deficiency is confirmed, GH therapy.
A comprehensive endocrine support panel covers: full HPG axis, full HPT axis, HPA axis, and insulin/IGF-1 axis.
The Interconnected Endocrine System
The HPA-HPG Interaction: Cortisol and Testosterone
The HPA and HPG axes share a common hypothalamic hub — and they compete for resources. Corticotropin-releasing hormone (CRH) activates ACTH/cortisol while simultaneously suppressing GnRH pulsatility. Glucocorticoids directly inhibit GnRH, reduce pituitary LH sensitivity, and directly inhibit testicular Leydig cell testosterone synthesis. The result: chronic HPA activation — from any cause — produces HPG suppression and testosterone decline. Cortisol pattern assessment (4-point diurnal cortisol) is a standard component of endocrine support evaluation for unexplained testosterone insufficiency.
The HPA-HPT Interaction: Cortisol and Thyroid Conversion
Thyroid hormone conversion from T4 to T3 is regulated by deiodinase enzymes (DIO1, DIO2). These are downregulated by glucocorticoids: elevated cortisol redirects T4 toward inactive reverse T3 (rT3). The result: normal or high T4, low-normal Free T3, and elevated reverse T3 — producing tissue-level hypothyroidism despite normal TSH. This pattern is particularly common in high-stress populations, inadequate sleep, overtraining athletes, caloric restriction, and chronic illness. Standard thyroid panels miss this because they don't measure Free T3 or reverse T3.
The Insulin-HPG Interaction: Metabolic Health and Hormones
Insulin resistance reduces hepatic SHBG production — which co-occurs with increased aromatase activity in adipose tissue, converting testosterone to estradiol. The net result in obese, insulin-resistant men is often low testosterone, low SHBG, and elevated estradiol. In women, insulin resistance is central to PCOS — characterized by hyperandrogenism, anovulation, and polycystic ovaries driven by insulin-mediated ovarian androgen hypersecretion.
Endocrine Support Assessment: The Full Panel
| Axis | Standard Markers | Extended/Functional Markers | Common Findings |
|---|---|---|---|
| HPG (gonadal) | Total T, LH, FSH | Free T, SHBG, estradiol, progesterone, prolactin | Low-normal T with elevated SHBG |
| HPT (thyroid) | TSH | Free T4, Free T3, reverse T3, antibodies | Low-normal Free T3 with normal TSH |
| HPA (adrenal) | Morning cortisol | 4-point salivary cortisol, DHEA-S | Flat diurnal curve; low DHEA-S |
| Insulin/metabolic | Fasting glucose, HbA1c | Fasting insulin, HOMA-IR, C-peptide, ApoB | Subclinical insulin resistance |
| GH/IGF-1 | Not standard | IGF-1, GH stimulation test | Low-normal IGF-1 with lifestyle contributors |
Endocrine Support Interventions
Supporting the HPT Axis: Beyond TSH Normalization
Standard thyroid management — levothyroxine (T4) titrated to normalize TSH — is appropriate for the majority of hypothyroid patients. But approximately 10–15% of patients on T4 monotherapy with normalized TSH continue to report persistent symptoms. The Endocrine Support program addresses this through: (1) reducing causes of impaired T4→T3 conversion (cortisol management, selenium adequacy, inflammation reduction), (2) optimizing T4 dosing to target TSH in lower-normal range (0.5–2.0 mIU/L), and (3) consideration of combination T4/T3 therapy where documented low Free T3 persists.
Supporting the HPA Axis: Cortisol Pattern and DHEA Balance
Adrenal support is not simply "adrenal fatigue" — a term that conflates a spectrum of HPA patterns into a single unsupported diagnosis. Clinically meaningful patterns include: morning cortisol insufficiency, elevated evening cortisol, elevated total daily cortisol output, and secondary DHEA-S deficiency. DHEA-S supplementation is indicated in documented deficiency. Cortisol pattern normalization relies primarily on addressing root causes — sleep optimization, stress management, exercise periodization.
Coordinating Across Axes
The priority order: (1) Stabilize HPA axis first — reducing chronic cortisol creates the hormonal environment for other axes to function. (2) Optimize metabolic health — improving insulin sensitivity reduces SHBG dysregulation, aromatase overactivity, and inflammation. (3) Optimize thyroid function — adequate Free T3 normalizes cellular metabolism. (4) Address HPG axis deficiencies — testosterone or estrogen optimization after upstream axes are stabilized produces better, more durable outcomes.
Frequently Asked Questions
Scientific References
- Endocrine Society. “Testosterone Therapy in Men with Hypogonadism.” JCEM. 2018.
- Garber JR, et al. “Clinical practice guidelines for hypothyroidism in adults.” Endocrine Practice. 2012.
- Arlt W, Callies F, et al. “DHEA replacement in women with adrenal insufficiency.” NEJM. 1999.
- Nieman LK. “Cushing's syndrome: pathophysiology, diagnosis and treatment.” Nature Reviews Endocrinology. 2015.
- Leproult R, Van Cauter E. “Effect of 1 week of sleep restriction on testosterone levels.” JAMA. 2011.
- American Urological Association. “Testosterone Deficiency Guideline.” 2022.
Begin Your Endocrine Support Program
Schedule a consultation for comprehensive multi-axis endocrine assessment.